Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on providing systemic administration of therapeutics to patients using our proprietary Adhesive Dermally-Applied Microneedle, or ADAM technology. Our lead clinical asset, Qtrypta*™ (M207) (zolmitriptan intracutaneous microneedle system), has completed the pivotal efficacy ZOTRIP trial, and is scheduled to complete our long-term safety study in Q1 2019. Zosano is focused on developing products where rapid administration of established molecules with known safety and efficacy profiles provides an increased benefit to patients, for markets where patients remain underserved by existing therapies.
Therapeutic blood levels obtained more rapidly than with oral administration.
Ready. Set. Apply. Three easy steps for administration.
We use known therapeutics with well-established safety and efficacy profiles.
Zosano Pharma’s investigational migraine treatment, ADAM Zolmitriptan Qtrypta (M207), is a novel formulation of zolmitriptan, a drug used orally and nasally to effectively and safely treat migraines, administered via the Company’s proprietary intracutaneous delivery system. Qtrypta (M207) is being investigated as a potential treatment to provide rapid relief of migraine symptoms, at any time in the migraine cycle, in a discreet and simple manner.
* Qtrypta (zolmitriptan intracutaneous microneedle system) is the proposed tradename that has been conditionally approved by FDA. Zosano will seek approval of the tradename when an NDA is filed for the product.